Emergent BioSolutions (NYSE:EBS) Posts Quarterly Earnings Results, Misses Expectations By $1.50 EPS
Emergent BioSolutions (NYSE:EBS – Get Rating) announced its earnings results on Tuesday. The biopharmaceutical company reported ($3.17) EPS for the quarter, missing the consensus estimate of ($1.67) by ($1.50), Briefing.com reports. Emergent BioSolutions had a negative net margin of 19.97% and a negative return on equity of 7.57%. The firm had revenue of $165.10 million […]